Trials in Cincinnati, Ohio
Here are the top 10 medical studies for alzheimer's disease in Cincinnati, Ohio
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
Donanemab for Alzheimer's Disease
Recruiting1 awardPhase 3
Indianapolis, Indiana
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Centerville, Ohio
This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Centerville, Ohio
This trial is testing whether semaglutide has a positive effect on early Alzheimer's disease by comparing it to a placebo. There will be 17 clinic visits and 1 phone call with the study doctor, and various tests and scans will be performed. The study will last for up to 173 weeks.
Monoclonal Antibodies
Donanemab for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Monoclonal Antibodies
Gantenerumab for Alzheimer's Disease
Recruiting0 awardsPhase 2 & 3
Indianapolis, Indiana
This trial will study if treatment with an investigational study drug can prevent or slow the rate of Alzheimer's disease (AD)-causing accumulation of amyloid beta (Aβ). Part 1 will use Aβ positron emission tomography (PET) imaging to determine if treatment with the study drug prevents or slows the rate of Aβ pathological disease accumulation. Part 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD.
Trials With No Placebo
Behavioural Intervention
Lifestyle Interventions for Early Onset Alzheimer's Disease
Recruiting1 award
Indianapolis, Indiana
This trial studies the effects of computer and Tai Chi-Qi Gong training on those with early-onset Alzheimer's. It is hoped that these activities can improve cognition, functioning, and mood.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.